<SEC-DOCUMENT>0001144204-14-074364.txt : 20141217
<SEC-HEADER>0001144204-14-074364.hdr.sgml : 20141217
<ACCEPTANCE-DATETIME>20141217093815
ACCESSION NUMBER:		0001144204-14-074364
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20141217
FILED AS OF DATE:		20141217
DATE AS OF CHANGE:		20141217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO BLAST PHARMA LTD.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		141291390

	BUSINESS ADDRESS:	
		STREET 1:		35 AHAD HA'AM ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			65202
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		35 AHAD HA'AM ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			65202
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v396831_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: December 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>BIO BLAST PHARMA LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">37 Dereh Menechem Begin St., 15<SUP>th</SUP>
Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Tel Aviv 6522042 Israel</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Form 20-F &nbsp;<FONT STYLE="font-family: Wingdings">x
</FONT>Form 40-F <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report of Foreign Private Issuer on
Form 6-K of the registrant consists of the press release issued by the registrant on December 17, 2014, announcing that the registrant
was issued a new patent by the United States Patent and Trademark Office, which is attached hereto as Exhibit 99.1 and incorporated
by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release issued by Bio Blast Pharma Ltd. on December 17, 2014.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 63%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Bio Blast Pharma Ltd. </U><BR>
        (Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
        By <U>/s/ Dalia Megiddo</U></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Dalia Megiddo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December 17, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v396831_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Immediate Release</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BioBlast Receives Notice of Patent Issuance
from USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich&rsquo;s Ataxia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TEL
AVIV, Israel, December 17, 2014</B> &ndash; Bio Blast Pharma Ltd, (NasdaqGM: ORPN) a clinical-stage biotechnology company committed
to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today it has received
a Notice of Patent Issuance for patent no. 8,912,147</FONT><FONT STYLE="color: #1F497D"> </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">from
the United States Patent and Trademark Office (USPTO) for a composition-of-matter patent for its novel fusion protein for Friedrich&rsquo;s
Ataxia (referred to as BB-FA) that is built on its mitochondrial protein replacement (mPRT) platform. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This patent covers the significant innovations we have
made in the delivery of therapeutic proteins into mitochondria,&rdquo; said Dalia Megiddo, MD, Chief Executive Officer of BioBlast.
&ldquo;We are pleased to have added to our patent and patent applications estate and look forward to making further progress toward
providing a therapy to help Friedrich&rsquo;s Ataxia patients in need of treatment.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Friedrich&rsquo;s Ataxia is an inherited disorder characterized
by progressive deterioration of the muscular and nervous system that begins in the first or second decade of life and results in
gait disturbance (ataxia), cognitive impairment, progressive heart disease and diabetes. According to Friedrich&rsquo;s Ataxia
Research Alliance (FARA), about 1:50,000 people in the U.S. suffer from Friedrich&rsquo;s Ataxia. Most patients are wheelchair-bound
within 15 years of diagnosis. Most patients do not survive beyond the fourth or fifth decade of life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Bio Blast</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioBlast Pharma is a clinical-stage biotechnology company committed
to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Founded in 2012, the company is rapidly building a diverse portfolio
of product candidates with the potential to address unmet medical needs for incurable diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The BioBlast platforms are based on deep understanding of the
disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.
For more information please visit the Company's website, www.bioblast-pharma.com, the content of which is not incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><IMG SRC="image_002.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
press release may contain forward-looking statements within the meaning of the &quot;safe harbor&quot; provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements
when we discuss</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">making further progress toward providing a therapy
to help Friedrich&rsquo;s Ataxia patients, or that our platforms potentially offer solutions for several diseases that share the
same biological pathology. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee
that the conclusions of future research or trials would not suggest different conclusions or that historic results would not be
interpreted differently in light of additional research and clinical and preclinical trials results. Because such statements deal
with future events and are based on Bio Blast Pharma Ltd.'s current expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of Bio Blast Pharma could differ materially from those described in or implied
by the statements in this press release, including those discussed under the heading &quot;Risk Factors&quot; in Bio Blast Pharma's
final IPO&rsquo;s prospectus filed with the Securities and Exchange Commission (SEC) and in any subsequent filings with the SEC.
Except as otherwise required by law, Bio Blast Pharma disclaims any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="Description: http:||l2.yimg.com|bt|api|res|1.2|Vu_9Io6cZ7VEWep70Xb4Jw--|YXBwaWQ9eW5ld3M7cT04NQ--|https:||www.globenewswire.com|newsroom|ti?nf=MTQ1IzEwMDkyMTMwIzMyNDU1" STYLE="height: 2px; width: 2px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Investor Contact<BR> Andrew McDonald <BR>
Founding Partner<BR>
LifeSci Advisors, LLC<BR> Andrew@lifesciadvisors.com<BR> 646-597-6987</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``U`/@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BHKBXAM
M('GGD"1H,LQ[5P6H>,+S5+TV6EM]FAYW3XRVT=3[4FU%7>PTFW9'H)90<$@'
MZTI(`R>E>6M>R1292665N[S-N8GU]JFOO%=]8^&YTEDS+,"D+'[WN?H*\W#Y
MMA\15]E3NWWMH=M7+ZU*G[2=DO74S_&OC.>^OY-/T^8I:1DJS*?]8>_X5E>&
MM<NM%O$DB<F(G]Y'GAA6#!9W5Q)F.&1^_`JW$KQ/MD4JP[$8KTSA/?[:=+JV
MCGB.4D4,I]JEKGO!5PUQX:@W'/EL4'T%=#0`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!Y;XZ\1M=:@^GPOBW@.&Q
M_$W_`-:L#0+I/[0>)B`TT3(A_P!H]!6%>27"W<JW((F#'>#ZU6$CA@P)!!R"
M*BK352#@]FK%0FX24ET/6M%\/#4[669IO+=6VJ"NX`^XK0_X0.R>03W$S7%Q
MC&Z5<J!Z!>U87@3Q=`\[6=^PBFD`"R$X5S[^AKTKMFN+`X&&&H^SMKU:Z_,Z
ML5BI5JG-?3HNQPVMZ))IEFLJ7I=5.-A&"/I7-:D@O]/E>0#SK="ZR=]HZ@UM
M>(M1BN/%KV*R!A):C9SQO["J^F:)<ZJ'B52L+_)(Q[+WQ[]*\JK0G1S*G["_
M++?5M>?<]"%6-7!3]K:Z\K>AU/@>!H/"UL6',I,@^AKE/$/B#7KSQL^BZ)=+
M$``F"<`-W)->DQ11VMJD4:@1QIA0/05XQI>EWGBOQ=JMW:7AM"K,_FCW.,?I
M7TIX9T'A[Q1K]KXO70=7DCN-S;2R<[3ZY]*UUEU*Z^(16#6H39Q#Y[19.<#J
M-OK[URG@&1-/\7W]I=I'/<JDA^U9R5V]<'WJ#PO=R13>)/$0YE@A8H3_`'F/
M'\J`/4[_`,1Z/ID_DWNHP0RXSL9N:M)J%M<:>UY;SI+!L+!U.17E'A;P]8:Q
MH.IZ[K4IE?Y@&9L;2!G)_.H/"E[+:>"_$K>8PB6-1%D\;CD<?I0!8TS6/&7B
M'[;<6%_&D5L=S*S;>N3@>O2NB\'>,;S5-%U)]1"F2RCW>:HQN!!Z^_%<1IWA
MN_?P5=:S!J1@CRV^#)4.H]ZU=+U*&'X5:DL<"Q2EO)=Q_'NZ&F(V_AA=WU__
M`&C=WES+*@*JGF-D#J3_`$KK;GQ7H-G.T-QJMLDB]5+9Q7EQU"XT/X;6D%N3
M'-J4SL7'!V#C%0^(=`T[0_"-@[?O-4NR)&?=T7'0#TY%(9[$-7T\Z?\`;_MD
M/V3KYN[Y:K6OB;1;XR"VU*"0QH7?:>BCO7GOB#P[J,O@31!90M(EO$6GC3J2
M>=V._>I_"4WAW4-'U';IOV6ZCM2DX5OOIW(/;I0!KV'Q$@OO%4FGDPPV*;@L
M[-_K"#Q^==E>7'V>QFG!^XA8&O)OAOX9L-7DNKR\B9Q`Z^3\V.>3_A7I/B67
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MJB74&!(JC`8=FKQFX\Z>9YI6+.YRQ/<UT/@"ZEM?%MJJ9Q+F-A[&O?ITU"$8
MKHK'D3FYR<N[N>UW,;S6TL:/L=U*AO2O.H/AA>6ID^SZX\0DX?8I&[ZX->E4
M59!R.D>`K31=/O([>=I+VXC,9N77E0?04[P_X(@TC1[[3[F;[0EYQ(0,<8KK
M**`/,U^%][%YMI#K3II\K9=`#S]1G!K?O/`ULWA0:'8S&!3()'E(R7(ZYKK:
M*`/-D^%UR;=;677)?LH.?+53C\LXK9U'P'!-X;AT6QN#;PI)YCLPW%V]3784
M4`<=J_@.'4O#5AIBW!26R7;'*1P?7-8K_"R6X@A-QJ\DDZ?+\PRJKV`KTNB@
M#C=;\):M>7,<VGZU);*L*Q&-<J,`>Q[T[0_`5MI&F7UN]RTL]['LDEQC:/:N
MPHH`XGPCX(NO#6J27#:@98"I41`$!L]S72:QI;:I"D0E\L*<GC.:TJ*SK4H5
MH.G-73+IU)4Y*4=T0VL`MK6*!3D(H7-9VK:,=4GB<S[$C&-N*UZ*BKAJ=6G[
M*:]W33T'"M.$^>+U,?5=$.I2PGSMB1#&W%,U?0!J$L<\4OERH`OU`Z5MT5E4
MR_#U.;FC\5K_`"V-(8JK#EY7MM\SG(O"YCO(KEKIG=2&;<.IJVNB?\3LZB\V
M[G(3'2MBBIAEN&AI&/6^[W74<L96EN^EOD9.K:,=4FA8S;%C[8ZTW4M$.H74
M$IFVI$`-N.M;%%7/`T*CDY1^*S?RV)CB:L;6>U[?,Q[_`$0WVH0W#382,`;,
M>E1:IX?-[>K=P3>5)QG\.];M%34R_#U%)2C\3N]7NAPQ=6%K/96.?M?#(MM1
MBNA<ERAW'<.2:*Z"BM</A:6'3C25D]2*M:=5IS=[!111709#719$9'4,K#!!
M&0:XS6O`6ER++=VS-;D`L4494_3THHH`\\N;%([KR0Q(SC.*]'\'>$[+3E34
M][2W#KA=PP$'?%%%`'8T444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
8`!1110`4444`%%%%`!1110`4444`?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``"``(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@#__
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
